Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation

Circulation Journal

Volumn 74, Issue 4, 2010, Pages 701-708

  Gao, Fei ^a   Zhou, Yu Jie ^a   Wang, Zhi Jian ^a   Shen, Hua ^a   Liu, Xiao Li ^a   Nie, Bin ^a   Yan, Zhen Xian ^a   Yang, Shi Wei ^a   Jia, de An ^a   Yu, Miao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Drug eluting stent; Dual antiplatelet therapy; Triple antithrombotic therapy; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOEMBOLISM; TICLOPIDINE; TREATMENT OUTCOME; WARFARIN;

EID: 77950680872     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0880     Document Type: Article

References (34)

1. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guide-lines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
3. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen J, Cuisset T, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13-28.
4. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726-732.
5. Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147: 463-467.
6. Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134: 559-567.
7. Konstantino Y, Iakobishvili Z, Porter A, Sandach A, Zahger D, Hod H, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006; 105: 80-85.
8. DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007; 27: 691-696.
9. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W): A randomized controlled trial. Lancet 2006; 367: 1903-1912.
10. Apostolakis S, Shantsila E, Lip GY, Lane DA. Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". Thromb Haemost 2009; 102: 914-915.
11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
12. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
13. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis In Myocardial Infarction (TIMI) Trial. Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
14. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944.
15. Rubboli A, Milandri M, Castelvetri C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting: Clues for the management of patients with an indication for long-term anticoagulation under-going coronary stenting. Cardiology 2005; 104: 101-106.
16. Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18: 162-164.
17. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008; 102: 1618-1623.
18. Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818-825.
19. Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke 2008; 39: 2736-2743.
20. Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, et al. GRACE Investigators. Combining warfarin and anti-platelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: Is it safe and effective to use just one anti-platelet agent? Eur Heart J 2007; 28: 1717-1722.
21. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al, BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of the drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
22. Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 2008; 51: 2220-2227.
23. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-168.
24. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
25. Kitahara H, Kobayashi Y, Takebayashi H, Fujimoto Y, Nakamura Y, Kuroda N, et al. Re-restenosis and target lesion revascularization after treatment of sirolimus-eluting stent restenosis: Retrospective analysis of 4 Japanese hospitals. Circ J 2009; 73: 867-871.
26. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997.
27. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 2009; 73: 615-621.
28. Honda Y. Drug-eluting stents: Insights from invasive imaging technologies. Circ J 2009; 73: 1371-1380.
29. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, et al. Long-term follow-up of neointimal coverage of sirolimus-eluting stents: Evaluation with optical coherence tomography. Circ J 2009; 73: 2300-2307.
30. Lee SE, John SH, Lim JH, Rhew JY. Very late stent thrombosis associated with multiple stent fractures and peri-stent aneurysm formation after sirolimus-eluting stent implantation. Circ J 2008; 72: 1201-1204.
31. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
32. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, et al. STENTICO Investigators. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009; 104: 338-342.
33. Zahger D, Ilia R. Coronary stenting in warfarin treated patients. EuroIntervention 2009; 5: 277-281.
34. Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009; 54: 95-109.